PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31866563-3	2020	In this study, we hypothesized that NCS-382 is a substrate for the monocarboxylate transporter subtype 1 (MCT1) which is known to mediate blood-brain barrier (BBB) permeation of GHB.	4-hydroxybutyric acid	178-181	solute carrier family 16 member 1	Homo sapiens	67-104	
33963018-13	2021	The results indicate that ethanol co-administered with GHB increases toxicity and MCT1 inhibition is effective in reversing toxicity by inhibiting GHB brain uptake when given post-GHB/ethanol administration.	4-hydroxybutyric acid	147-150	solute carrier family 16 member 1	Homo sapiens	82-86	
33963018-13	2021	The results indicate that ethanol co-administered with GHB increases toxicity and MCT1 inhibition is effective in reversing toxicity by inhibiting GHB brain uptake when given post-GHB/ethanol administration.	4-hydroxybutyric acid	147-150	solute carrier family 16 member 1	Homo sapiens	82-86	
33963018-15	2021	The effects of the novel MCT1 inhibitors AR-C155858 and AZD-3965 on this drug-drug interaction have not been studied before, and our preclinical studies indicate that MCT1 inhibitors can decrease brain concentrations of GHB by inhibiting brain uptake, even when administered at times after GHB/ethanol.	4-hydroxybutyric acid	220-223	solute carrier family 16 member 1	Homo sapiens	25-29	
33963018-15	2021	The effects of the novel MCT1 inhibitors AR-C155858 and AZD-3965 on this drug-drug interaction have not been studied before, and our preclinical studies indicate that MCT1 inhibitors can decrease brain concentrations of GHB by inhibiting brain uptake, even when administered at times after GHB/ethanol.	4-hydroxybutyric acid	220-223	solute carrier family 16 member 1	Homo sapiens	167-171	
33963018-15	2021	The effects of the novel MCT1 inhibitors AR-C155858 and AZD-3965 on this drug-drug interaction have not been studied before, and our preclinical studies indicate that MCT1 inhibitors can decrease brain concentrations of GHB by inhibiting brain uptake, even when administered at times after GHB/ethanol.	4-hydroxybutyric acid	290-293	solute carrier family 16 member 1	Homo sapiens	25-29	
33963018-15	2021	The effects of the novel MCT1 inhibitors AR-C155858 and AZD-3965 on this drug-drug interaction have not been studied before, and our preclinical studies indicate that MCT1 inhibitors can decrease brain concentrations of GHB by inhibiting brain uptake, even when administered at times after GHB/ethanol.	4-hydroxybutyric acid	290-293	solute carrier family 16 member 1	Homo sapiens	167-171	
31866563-3	2020	In this study, we hypothesized that NCS-382 is a substrate for the monocarboxylate transporter subtype 1 (MCT1) which is known to mediate blood-brain barrier (BBB) permeation of GHB.	4-hydroxybutyric acid	178-181	solute carrier family 16 member 1	Homo sapiens	106-110	
17502341-1	2007	Monocarboxylate transporter 1 (MCT1) is an important determinant of the renal transport of the drug of abuse, gamma-hydroxybutyric acid (GHB).	4-hydroxybutyric acid	110-135	solute carrier family 16 member 1	Homo sapiens	0-29	
17502341-1	2007	Monocarboxylate transporter 1 (MCT1) is an important determinant of the renal transport of the drug of abuse, gamma-hydroxybutyric acid (GHB).	4-hydroxybutyric acid	110-135	solute carrier family 16 member 1	Homo sapiens	31-35	
17502341-1	2007	Monocarboxylate transporter 1 (MCT1) is an important determinant of the renal transport of the drug of abuse, gamma-hydroxybutyric acid (GHB).	4-hydroxybutyric acid	137-140	solute carrier family 16 member 1	Homo sapiens	0-29	
17502341-1	2007	Monocarboxylate transporter 1 (MCT1) is an important determinant of the renal transport of the drug of abuse, gamma-hydroxybutyric acid (GHB).	4-hydroxybutyric acid	137-140	solute carrier family 16 member 1	Homo sapiens	31-35